BioCentury | Nov 12, 2012
Clinical News

Misoprostol vaginal insert regulatory update

...for the product (see BioCentury, Oct. 29). Ferring gained MVDS through its 2011 acquisition of Cytokine PharmaSciences Inc....
BioCentury | Oct 29, 2012
Clinical News

Misoprostol vaginal insert regulatory update

...product was submitted in the EU. Ferring gained the product through its 2011 acquisition of Cytokine PharmaSciences Inc....
BioCentury | Oct 31, 2011
Company News

Cytokine PharmaSciences, Ferring deal

...is a sustained release vaginal insert delivery a synthetic prostaglandin E2. Terms were not disclosed. Cytokine PharmaSciences Inc....
BioCentury | Jul 12, 2010
Clinical News

Misoprostol vaginal insert: Phase II data

...vaginal insert were well tolerated. The most common adverse event was non-reassuring fetal heart rate. Cytokine PharmaSciences Inc....
BioCentury | Jun 10, 2010
Cover Story

Unique pathway in diabetes

...of a eukaryotic translation initiation factor 5A small interfering RNA in preclinical development for diabetes. Cytokine PharmaSciences Inc....
...Osherovich, L. SciBX 3 (23); doi:10.1038/scibx.2010.692 Published online June 10, 2010 Companies and Institutions Mentioned Cytokine PharmaSciences Inc....
BioCentury | Dec 7, 2009
Clinical News

CPSI-2364: Phase I data

...oral CPSI-2364 were well tolerated with no serious adverse events. The MTD was not reached. Cytokine PharmaSciences Inc....
BioCentury | Jul 27, 2009
Clinical News

CPSI-2364: Phase I started

...company began a dose-escalation Phase I trial to evaluate oral CPSI-2364 in 36 healthy volunteers. Cytokine PharmaSciences Inc....
BioCentury | Aug 14, 2008
Targets & Mechanisms

Shockproofing Against Sepsis

...inhibition and the TLR blockade," said Vidal de la Cruz, VP of business development at Cytokine PharmaSciences Inc....
...and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cytokine PharmaSciences Inc....
BioCentury | Jul 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...steps include determining the mechanism of neuroprotection and studies in additional mouse models of AD. Cytokine PharmaSciences Inc.'s...
...Phase I trial as an adjunct to IL-2 in cancer. Patent application filed; licensed to Cytokine PharmaSciences...
BioCentury | Apr 14, 2008
Emerging Company Profile

Corporate Profile

...2006 by Omar Haffar, Antoun Nabhan and David Jobes University collaborators: Stanford University Corporate partners: Cytokine PharmaSciences Inc....
Items per page:
1 - 10 of 30
BioCentury | Nov 12, 2012
Clinical News

Misoprostol vaginal insert regulatory update

...for the product (see BioCentury, Oct. 29). Ferring gained MVDS through its 2011 acquisition of Cytokine PharmaSciences Inc....
BioCentury | Oct 29, 2012
Clinical News

Misoprostol vaginal insert regulatory update

...product was submitted in the EU. Ferring gained the product through its 2011 acquisition of Cytokine PharmaSciences Inc....
BioCentury | Oct 31, 2011
Company News

Cytokine PharmaSciences, Ferring deal

...is a sustained release vaginal insert delivery a synthetic prostaglandin E2. Terms were not disclosed. Cytokine PharmaSciences Inc....
BioCentury | Jul 12, 2010
Clinical News

Misoprostol vaginal insert: Phase II data

...vaginal insert were well tolerated. The most common adverse event was non-reassuring fetal heart rate. Cytokine PharmaSciences Inc....
BioCentury | Jun 10, 2010
Cover Story

Unique pathway in diabetes

...of a eukaryotic translation initiation factor 5A small interfering RNA in preclinical development for diabetes. Cytokine PharmaSciences Inc....
...Osherovich, L. SciBX 3 (23); doi:10.1038/scibx.2010.692 Published online June 10, 2010 Companies and Institutions Mentioned Cytokine PharmaSciences Inc....
BioCentury | Dec 7, 2009
Clinical News

CPSI-2364: Phase I data

...oral CPSI-2364 were well tolerated with no serious adverse events. The MTD was not reached. Cytokine PharmaSciences Inc....
BioCentury | Jul 27, 2009
Clinical News

CPSI-2364: Phase I started

...company began a dose-escalation Phase I trial to evaluate oral CPSI-2364 in 36 healthy volunteers. Cytokine PharmaSciences Inc....
BioCentury | Aug 14, 2008
Targets & Mechanisms

Shockproofing Against Sepsis

...inhibition and the TLR blockade," said Vidal de la Cruz, VP of business development at Cytokine PharmaSciences Inc....
...and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cytokine PharmaSciences Inc....
BioCentury | Jul 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...steps include determining the mechanism of neuroprotection and studies in additional mouse models of AD. Cytokine PharmaSciences Inc.'s...
...Phase I trial as an adjunct to IL-2 in cancer. Patent application filed; licensed to Cytokine PharmaSciences...
BioCentury | Apr 14, 2008
Emerging Company Profile

Corporate Profile

...2006 by Omar Haffar, Antoun Nabhan and David Jobes University collaborators: Stanford University Corporate partners: Cytokine PharmaSciences Inc....
Items per page:
1 - 10 of 30